Results 51 to 60 of about 28,619 (164)
The ketogenic diet alters microbiome‐metabolome profiles to improve West syndrome therapy
The ketogenic diet alleviates West syndrome by reshaping gut microbiota (increasing Bacteroides, Parabacteroides, and reducing Escherichia and Bifidobacterium), and modulating metabolites—including anticonvulsant lipids (e.g., capric acid), suppressed harmful lipids (e.g., 2‐methylbutyroylcarnitine), and amino acids and analogs (e.g., 3‐sulfinoalanine)—
Gan Xie +5 more
wiley +1 more source
Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation
Tregs control immune tolerance but can also enable tumor escape. Nanomaterials can now expand or stabilize Tregs to treat autoimmunity and support transplantation or conversely disrupt tumor Tregs to boost antitumor immunity. We also discuss unintended Treg modulation by nanoparticles, safety and manufacturing challenges, and future translational ...
Yiyin Chen +10 more
wiley +1 more source
Role of Metabotropic Glutamate Receptors in Neurological Disorders
Glutamate is a fundamental excitatory neurotransmitter in the mammalian central nervous system (CNS), playing key roles in memory, neuronal development, and synaptic plasticity.
Rosalia Crupi +3 more
doaj +1 more source
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller +3 more
wiley +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Background and Purpose Riluzole, approved for amyotrophic lateral sclerosis (ALS), has a glutamate‐modulating profile favourable for mitigating opioid addiction. It reduces neuronal glutamate release and enhances glutamate reuptake, offering advantages over agents that only increase glutamate reuptake.
Ewa Galaj +7 more
wiley +1 more source
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan +2 more
wiley +1 more source
Deleterious mutations in the glutamate receptor metabotropic 1 gene (GRM1) cause a recessive form of cerebellar ataxia, SCAR13. GRM1 and GRM5 code for the metabotropic glutamate type 1 (mGlu1) and type 5 (mGlu5) receptors, respectively.
Simone Bossi +11 more
doaj +1 more source
Abstract Background and Purpose Pharmacological inhibition of TRPC4 and/or TRPC5 channels reduces Pavlovian aversion memory in stressed mice and reduces amygdala reactivity to aversion in humans with depression. The aims of this mouse study were to improve understanding of these anxiolytic processes, determine whether there are corrective effects on ...
Giulia Poggi +14 more
wiley +1 more source

